Web3. sep 2024 · PHESGO被指定与化疗联合使用,用于 作为早期乳腺癌(EBC)完全治疗方案的一部分,对患有HER2阳性,局部晚期,炎性或早期乳腺癌(直径大于2 cm或淋巴结阳性)的患者进行单辅助治疗。 HER2阳性早期乳腺癌患者的辅助治疗高复发风险。 2. 转移性乳腺癌(MBC) 与多西紫杉醇联合使用用于治疗尚未接受过抗HER2先前疗法或化疗的HER2阳性转 … Web18. mar 2024 · Phesgo should only be initiated under the supervision of a physician experienced in the administration of anti-cancer agents. Phesgo should be administered …
PHESGO, 1200MG/600MG INJ SOL 1X15ML, Státní ústav pro …
Web10. júl 2024 · On June 29, the Food and Drug Administration (FDA) announced its approval of Phesgo, an under-the-skin injection that can be used at home for early or metastatic HER2-positive breast cancer. 1. The FDA approved Phesgo four months ahead of schedule in response to the coronavirus (COVID-19) pandemic, allowing patients to limit their … Web6 Wochen oder mehr beträgt, ist erneut eine Initialdosis von Phesgo 1.200 mg/600 mg zu verabreichen, gefolgt von der Erhaltungsdosis von Phesgo 600 mg/600 mg alle 3 Wochen. Dosierungsanpassungen Eine Dosisreduktion von Phesgo wird nicht empfohlen. Ein Absetzen der Behandlung mit Phesgo kann nach Ermessen des Arztes erforderlich sein. casa sanchez jerez
AUSTRALIAN PRODUCT INFORMATION Phesgo (pertuzumab and …
WebLiečba liekom Phesgo sa má prerušiť aspoň na 3 týždne pri poklese hodnoty LVEF na menej ako 50 %, ktorá zároveň predstavuje pokles o ≥ 10 % oproti hodnote pred začiatkom liečby. Liečba liekom Phesgo sa môže opätovne začať, keď sa hodnota LVEF upraví na ≥ 50 %, alebo keď je rozdiel < 10 % oproti hodnote pred začiatkom liečby. WebPhesgo® contém pertuzumabe e trastuzumabe, que são anticorpos monoclonais recombinantes humanizados direcionados contra a proteína HER2 da célula de câncer, e fazem com que ela pare de se multiplicar e se autodestrua. Além disso, pertuzumabe e trastuzumabe agem na toxicidade celular por meio de determinados anticorpos do … WebPatient satisfaction with Phesgo is compared to conventional intravenous pertuzumab & trastuzumab. ... The continued monitoring of patient waiting times and inventory management will ensure the system remains fit for purpose and is adapting to changes in patient needs and the NHS commissioning environment. casa san jose obrero jerez